Chiara Maura Ciniselli1, Maida De Bortoli2, Elena Taverna2, Luca Varinelli2, Sara Pizzamiglio1, Silvia Veneroni3, Chiara Bonini4, Rosaria Orlandi5, Paolo Verderio1, Italia Bongarzone2. 1. a Unit of Medical Statistics, Biometry and Bioinformatics , Fondazione IRCCS Istituto Nazionale dei Tumori , Milan , Italy. 2. b Laboratory of Proteomics , Fondazione IRCCS Istituto Nazionale dei Tumori , Milan , Italy. 3. c Biomarkers Unit , Fondazione IRCCS Istituto Nazionale dei Tumori , Milan , Italy. 4. d Laboratory Medicine , Fondazione IRCCS Istituto Nazionale dei Tumori , Milan , Italy. 5. e Molecular Targeting Unit , Fondazione IRCCS Istituto Nazionale dei Tumori , Milan , Italy.
Abstract
OBJECTIVE: Hepcidin-25 production is stimulated by systemic inflammation, and it interferes with iron utilization, leading to anemia. This study aimed to investigate the relationships between the plasma levels of hepcidin, interleukin-6 (IL-6), erythropoietin (EPO) and erythroferrone (ERFE) in patients with benign breast disease or cancer. METHODS: Plasma samples from a cohort of 131 patients (47 with benign breast disease and 84 with breast cancer) were subjected to the evaluation of hepcidin, IL-6, EPO and ERFE using SELDI-TOF-MS or immunoassays. RESULTS: An elevated hepcidin was observed in malignant breast tumors compared to benign ones. No correlation was observed between hepcidin and IL-6, EPO or ERFE. CONCLUSION: Since the study included a cohort of patients (87%) with breast cancers smaller than 2 cm, these results may support our previous evidence about the potential role of hepcidin in breast cancer disease.
OBJECTIVE:Hepcidin-25 production is stimulated by systemic inflammation, and it interferes with iron utilization, leading to anemia. This study aimed to investigate the relationships between the plasma levels of hepcidin, interleukin-6 (IL-6), erythropoietin (EPO) and erythroferrone (ERFE) in patients with benign breast disease or cancer. METHODS: Plasma samples from a cohort of 131 patients (47 with benign breast disease and 84 with breast cancer) were subjected to the evaluation of hepcidin, IL-6, EPO and ERFE using SELDI-TOF-MS or immunoassays. RESULTS: An elevated hepcidin was observed in malignant breast tumors compared to benign ones. No correlation was observed between hepcidin and IL-6, EPO or ERFE. CONCLUSION: Since the study included a cohort of patients (87%) with breast cancers smaller than 2 cm, these results may support our previous evidence about the potential role of hepcidin in breast cancer disease.
Entities:
Keywords:
BMP6; IL-6; benign breast disease; breast cancer; early diagnosis; erytroferrone; erytropoiesis; erytropoietin; hepcidin; inflammation; iron metabolism
Authors: Sara Pizzamiglio; Maida De Bortoli; Elena Taverna; Michele Signore; Silvia Veneroni; William Chi-Shing Cho; Rosaria Orlandi; Paolo Verderio; Italia Bongarzone Journal: Int J Mol Sci Date: 2017-02-14 Impact factor: 5.923
Authors: Katarzyna J Jerzak; Ana E Lohmann; Marguerite Ennis; Elizabeta Nemeth; Tomas Ganz; Pamela J Goodwin Journal: Breast Cancer Res Treat Date: 2020-09-22 Impact factor: 4.872